Journal article
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
- Abstract:
-
PURPOSE: The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety profile of irinotecan in combination with capecitabine, to identify a recommended dose and to determine the response rate and time to disease progression. In addition, we aimed to explore the pharmacokinetic parameters of irinotecan and capecitabine when used in different sequences of administration, with irinotecan infusion either prior...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
- Volume:
- 16
- Issue:
- 7
- Pages:
- 1123-1132
- Publication date:
- 2005-07-01
- DOI:
- EISSN:
-
1569-8041
- ISSN:
-
0923-7534
- Source identifiers:
-
236999
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:236999
- UUID:
-
uuid:62ddc9cb-bf84-42c2-90f4-27e1eeab97c3
- Local pid:
- pubs:236999
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2005
If you are the owner of this record, you can report an update to it here: Report update to this record